Trade iShares 1-3 Year Treasury Bond ETF - SHY
The investment seeks to track the investment results of the ICE® U.S. Treasury 1-3 Year Bond Index (the "underlying index").The fund will invest at least 80% of its assets in the component securities of the underlying index and it will invest at least 90% of its assets in U.S. Treasury securities that BFA believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the U.S. Treasury that have a remaining maturity of greater than or equal to one year and less than three years. This popular ETF offers exposure to the short end of the maturity curve, focusing on securities with less than three years to maturity. SHY can be a great safe haven to park assets in volatile markets, but won’t deliver much in the way of current yield.Latest shares articles

BNP Paribas stock forecast: Q2 earnings beat estimates
BNP Paribas is a French banking group whose recent developments include a Swift ledger transaction with HSBC for Siemens and continued focus on eurozone interest rates. Explore third-party BNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
14 hours ago

Boeing stock forecast: FAA investigates Miami freighter crash
Boeing is a US aerospace manufacturer whose shares remain in focus after a 767-300 freighter crash in Miami prompted an FAA investigation. Explore third-party BA price targets and technical analysis. Past performance is not a reliable indicator of future results.
14 hours ago

CaixaBank stock forecast: BPI exits Angola market
CaixaBank is a Spanish bank whose Portuguese unit, Banco BPI, agreed to sell its 33.35% stake in Banco de Fomento de Angola for €388.5m. Explore third-party CABK price targets and technical analysis. Past performance is not a reliable indicator of future results.
15 hours ago

Valneva stock forecast: EMA validates Lyme vaccine application
Valneva is a French vaccine company listed on Euronext Paris. In August, the EMA validated the marketing-authorisation application for its Lyme disease vaccine candidate with Pfizer. Explore third-party VLA price targets. Past performance is not a reliable indicator of future results.
19 hours ago